Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

A mobile prostate cancer screening program proved feasible for men in underserved neighborhoods and led to a high rate of ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

He revealed, “The aim of radiation therapy is to deliver a precise measured dose of radiation to a defined tumour volume with ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

As you navigate the challenges of prostate cancer and erectile dysfunction, remember that you are not alone. With advances in ...